The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered

Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as the most prevalent cause of chronic liver disease worldwide, driven by the global rise in obesity, type 2 diabetes mellitus, and metabolic syndrome. It currently affects approximately 38% of the adult population globally, with nearly a 50% increase in prevalence over the past decade.1 This upward trend is projected to persist in the coming years.2 This growing burden of MASLD highlights the urgent need for greater clinical awareness and intensified research efforts aimed at developing precision diagnostics and targeted therapeutic strategies.3 In their comprehensive review, Yeh et al4 summarize the multifaceted pathogenesis, diagnostic algorithms, natural history prediction models, and promising therapeutic strategies for MASLD, metabolic dysfunction–associated steatohepatitis (MASH), and MASLD-related hepatocellular carcinoma (HCC). They elucidate the complex pathophysiology of MASLD, which is driven by a multiple-hit hypothesis involving metabolic, genetic, and environmental factors. The key mechanisms, including insulin resistance, oxidative stress, gut–liver axis dysregulation, and genetic/epigenetic modifiers, contribute to the progression from simple steatosis to inflammation, fibrosis, and ultimately carcinogenesis.5,6 The review highlights novel mechanistic insights, such as m6A RNA methylation promoting lipogenic reprogramming, and gut microbial metabolites modulating hepatic immune surveillance via CXCL16-NKT cell axis, both of which offer promising therapeutic opportunities. By integrating single-cell transcriptomics, polygenic risk modeling, and liquid-biopsy biomarker development,7 the authors present a comprehensive framework to characterize MASLD heterogeneity and identify high-risk patients before irreversible liver damage occurs. A key strength of this review is its clear, side-by-side comparison of noninvasive scoring systems (such as fibrosis-4 index [FIB-4], aspartate transaminase [AST] to platelet ratio index [APRI], fibroScan-AST Score [FAST], and enhanced liver fibrosis test [ELF]), imaging modalities (eg, FibroScan and magnetic resonance elastography), and circulating biomarkers (including M2BPGi and miRNA panels), all of which have significantly advanced the evaluation of liver fibrosis and steatosis.8,9 This comprehensive synthesis enables clinicians to tailor diagnostic strategies according to resource availability and patient risk profiles, thereby reducing reliance on liver biopsy. Notably, the authors highlight emerging composite scores such as the Agile 3+ algorithm that incorporate demographic, laboratory, and elastography data to enhance the detection of advanced fibrosis.10 Lifestyle modification, aimed at achieving a 5% to 10% reduction in body weight through Mediterranean-style diets and structured exercise, remains the cornerstone of MASLD management, with proven benefits in reducing steatosis, resolving inflammation, and promoting fibrosis regression.3 This review provides a comprehensive analysis of emerging pharmacological therapies for MASLD. Thyroid hormone receptor-β agonists (eg, resmetirom), FXR agonists (eg, obeticholic acid), pan-peroxisome proliferator-activated receptor (PPAR) agonists (eg, lanifibranor), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and multi-incretin receptor co-agonists (eg, tirzepatide, retatrutide) have all demonstrated encouraging phase II-III data for steatohepatitis resolution and fibrosis improvement.11–13 The recent U.S. Food and Drug Administration (FDA) approval of resmetirom marks a significant milestone, but head-to-head comparisons and long-term safety studies will be critical to define optimal patient selection and combination treatment strategies.14 For patients with severe obesity and metabolic dysfunction, bariatric surgery represents a viable therapeutic option. The review highlights how surgical interventions such as gastric bypass and sleeve gastrectomy can result in significant improvements in liver histology and overall metabolic profiles. However, optimal outcomes depend on careful patient selection and thorough preoperative evaluation to minimize perioperative risks and long-term complications.15 In conclusion, this review provides a state-of-the-art roadmap for clinicians and researchers managing the growing MASLD epidemic. By elucidating the complex pathophysiology, advancing noninvasive diagnostic approaches, and emerging therapeutic innovations, it provides the foundation for precision medicine in MASLD. As the field transitions from descriptive epidemiology to targeted interventions, future progress will depend on the adoption of harmonized definitions, validated biomarkers, and multicenter collaborative clinical trials. A deeper understanding of the underlying mechanisms, combined with continued advancements in diagnostics and therapeutics, holds a significant promise for improving outcomes in this increasingly prevalent condition.